Discovery BMMCs provide post-thaw blast (CD45lo) and plasma cell (CD138+CD38+) counts via flow cytometry. Additionally, blast percentages are taken from the diagnostic Bone Marrow report obtained from the patient’s electronic medical record.
White Paper - Companion Diagnostic Development: An Overview
Primary Human Mast Cells are Now Available
Xenium In Situ Services are Now Available
Improving Pathology Precision in Oncology: How AI Reduces Variability in Tumor Percent Assignments
Advancing In Vitro Disease Modeling with Mouse Hepatocytes for Gene Therapy
White Paper - Companion Diagnostic Development: An Overview
Primary Human Mast Cells are Now Available
Xenium In Situ Services are Now Available
Improving Pathology Precision in Oncology: How AI Reduces Variability in Tumor Percent Assignments
Advancing In Vitro Disease Modeling with Mouse Hepatocytes for Gene Therapy